Accepted_test

Glioblastoma (GBM) is the most common and highly malignant of primary brain tumours in adults. Its aggressiveness is largely determined by its ability to invade - active invasion of individual malignant cells or groups of cells into the surrounding brain tissue. The modern standard of treatment of patients with glioblastoma includes maximal radical surgical resection of the tumour followed by radiation therapy and adjuvant chemotherapy with temozolomide, but this scheme does not ensure long-term survival of patients (median survival is 12-15 months from the moment of diagnosis, and 5-year survival rate of patients with GBM does not exceed 5%). At the same time, it is known that more than half of operated patients with GBM develop tumour recurrence rather quickly directly at the site of the postoperative cavity or in its marginal zone (not more than 2 cm from the cavity), and about 20% of patients develop distant tumour recurrences. GBM recurrences, which are the key reason of low survival rate of operated patients, are explained by the processes of invasion, in the first case - back invasion (reinvasion) of GBM cells, which have already migrated from the primary tumour, back into the area of the postoperative cavity, in the second case - invasion into the brain regions distant from the primary tumour. Molecular and cellular mechanisms of GBM invasion are currently being actively investigated in vitro and in animal models, but in clinical practice there are currently no approaches to GBM chemotherapy based on suppression of GBM cell invasion.